As of 2025-05-30, the Intrinsic Value of Inozyme Pharma Inc (INZY) is -8.26 USD. This INZY valuation is based on the model Peter Lynch Fair Value. With the current market price of 3.95 USD, the upside of Inozyme Pharma Inc is -309.24%.
Based on its market price of 3.95 USD and our intrinsic valuation, Inozyme Pharma Inc (INZY) is overvalued by 309.24%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -8.26 - -8.26 | -8.26 | -309.24% |
| P/E | (18.35) - (31.37) | (24.46) | -719.3% |
| DDM - Stable | (11.03) - (41.47) | (26.25) | -764.5% |
| DDM - Multi | (0.16) - (0.47) | (0.24) | -106.1% |
| Market Cap (mil) | 255.01 |
| Beta | 5.66 |
| Outstanding shares (mil) | 64.56 |
| Enterprise Value (mil) | 275.45 |
| Market risk premium | 4.60% |
| Cost of Equity | 11.04% |
| Cost of Debt | 5.00% |
| WACC | 9.92% |